In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputations

Butt JH, Kondo T, Yang M, et al. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023;44:2170-2183. 37220172.